PCSK9 drugs

Pharma

Amgen's Repatha meets the mark in CV primary prevention trial

On the heels of a label expansion in August, Amgen is touting another potential avenue to extend the value of its aging PCSK9 cholesterol med Repatha.

Fraiser Kansteiner Oct 2, 2025 11:26am

verdict damages punitive damages compensatory damages lawsuit

Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit

May 15, 2025 3:52pm

Amgen hits back at Sanofi, Regeneron in long-running patent feud

Mar 9, 2023 9:38am